(IRTC) iRhythm Technologies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4500561067

Patch Monitor, Monitoring Service, ECG Software, Gateway

IRTC EPS (Earnings per Share)

EPS (Earnings per Share) of IRTC over the last years for every Quarter: "2020-03": -0.33774343421548, "2020-06": -0.75200724152396, "2020-09": -0.1667367790604, "2020-12": -0.33354415286836, "2021-03": -0.95249687975751, "2021-06": -0.59210952661935, "2021-09": -0.80723727625877, "2021-12": -1.1036645017528, "2022-03": -1.7099772606711, "2022-06": -0.8007546132942, "2022-09": -0.71372008837073, "2022-12": -0.6699059717086, "2023-03": -1.2908538799221, "2023-06": -0.60592748016524, "2023-09": -0.88594112457934, "2023-12": -1.2604716305127, "2024-03": -1.4715625302098, "2024-06": -0.64559319312891, "2024-09": -1.4772567334144, "2024-12": -0.04252943240915, "2025-03": -0.97182652738208, "2025-06": -0.45007913896803,

IRTC Revenue

Revenue of IRTC over the last years for every Quarter: 2020-03: 63.535, 2020-06: 50.878, 2020-09: 71.944, 2020-12: 78.809, 2021-03: 74.311, 2021-06: 81.278, 2021-09: 85.432, 2021-12: 81.804, 2022-03: 92.378, 2022-06: 102.051, 2022-09: 103.875, 2022-12: 112.617, 2023-03: 111.436, 2023-06: 124.13, 2023-09: 124.604, 2023-12: 132.511, 2024-03: 131.929, 2024-06: 148.047, 2024-09: 147.538, 2024-12: 164.325, 2025-03: 158.677, 2025-06: 186.687,

Description: IRTC iRhythm Technologies

iRhythm Technologies Inc (NASDAQ:IRTC) is a digital healthcare company specializing in ambulatory cardiac monitoring services, primarily in the United States. The companys flagship product is the Zio ambulatory cardiac monitoring system, which includes various iterations such as Zio Monitor System, Zio XT System, and Zio AT System. These systems are prescription-only remote electrocardiogram (ECG) monitoring devices that record heart activity continuously for up to 14 days.

From a business perspective, iRhythms revenue growth is a key performance indicator (KPI). With a strong presence in the US market, the companys ability to expand its customer base and increase sales of its Zio monitoring systems will be crucial. Another important metric is the average revenue per user (ARPU), which can indicate the companys pricing power and ability to upsell or cross-sell its services. Additionally, the companys partnerships, such as its development collaboration agreement with Verily Life Sciences LLC, can be a significant driver of growth and innovation.

Analyzing iRhythms financials, we can observe that the company has a market capitalization of approximately $4.34 billion. The lack of a reported P/E ratio is not surprising, given the companys negative return on equity (RoE) of -112.84%. This suggests that iRhythm is currently unprofitable, which is not uncommon for growth-stage companies in the healthcare technology space. To gauge the companys financial health, we can examine its cash burn rate, operating expenses, and revenue growth rate. These metrics will be essential in determining iRhythms ability to achieve profitability in the future.

From a trading perspective, iRhythms stock has shown significant volatility, with an average true range (ATR) of 3.76, representing a 2.80% daily price movement. The stock is currently trading near its support and resistance levels, with key resistance levels at $153.8, $147.9, and $140.1, and support levels at $105.9, $98.5, and $87.4. A break above or below these levels could indicate a significant shift in the stocks price action.

IRTC Stock Overview

Market Cap in USD 5,673m
Sub-Industry Health Care Equipment
IPO / Inception 2016-10-20

IRTC Stock Ratings

Growth Rating 30.6%
Fundamental 39.7%
Dividend Rating -
Return 12m vs S&P 500 133%
Analyst Rating 4.62 of 5

IRTC Dividends

Currently no dividends paid

IRTC Growth Ratios

Growth Correlation 3m 61%
Growth Correlation 12m 93.3%
Growth Correlation 5y -18.9%
CAGR 5y -2.66%
CAGR/Max DD 5y -0.03
Sharpe Ratio 12m 1.54
Alpha 144.00
Beta 0.968
Volatility 40.96%
Current Volume 350.1k
Average Volume 20d 407.3k
Stop Loss 175.2 (-3.2%)
Signal 0.01

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (-92.4m TTM) > 0 and > 6% of Revenue (6% = 39.4m TTM)
FCFTA 0.03 (>2.0%) and ΔFCFTA 12.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 80.90% (prev 107.9%; Δ -27.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.07 (>3.0%) and CFO 63.3m > Net Income -92.4m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 5.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (31.6m) change vs 12m ago 1.43% (target <= -2.0% for YES)
Gross Margin 69.78% (prev 67.19%; Δ 2.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 69.80% (prev 58.43%; Δ 11.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -6.90 (EBITDA TTM -65.4m / Interest Expense TTM 12.4m) >= 6 (WARN >= 3)

Altman Z'' -0.69

(A) 0.55 = (Total Current Assets 663.9m - Total Current Liabilities 132.2m) / Total Assets 964.0m
(B) -0.83 = Retained Earnings (Balance) -803.8m / Total Assets 964.0m
(C) -0.09 = EBIT TTM -85.7m / Avg Total Assets 941.6m
(D) -0.93 = Book Value of Equity -803.8m / Total Liabilities 860.4m
Total Rating: -0.69 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 39.71

1. Piotroski 4.0pt = -1.0
2. FCF Yield 0.48% = 0.24
3. FCF Margin 4.24% = 1.06
4. Debt/Equity 6.41 = -2.50
5. Debt/Ebitda -10.15 = -2.50
6. ROIC - WACC -20.27% = -12.50
7. RoE -104.7% = -2.50
8. Rev. Trend 97.90% = 4.89
9. Rev. CAGR 23.76% = 2.50
10. EPS Trend 18.76% = 0.47
11. EPS CAGR 15.44% = 1.54

What is the price of IRTC shares?

As of September 06, 2025, the stock is trading at USD 181.05 with a total of 350,081 shares traded.
Over the past week, the price has changed by +6.51%, over one month by +12.92%, over three months by +24.66% and over the past year by +177.64%.

Is iRhythm Technologies a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, iRhythm Technologies (NASDAQ:IRTC) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 39.71 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IRTC is around 176.70 USD . This means that IRTC is currently overvalued and has a potential downside of -2.4%.

Is IRTC a buy, sell or hold?

iRhythm Technologies has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy IRTC.
  • Strong Buy: 9
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the IRTC price?

Issuer Target Up/Down from current
Wallstreet Target Price 182.6 0.9%
Analysts Target Price 182.6 0.9%
ValueRay Target Price 197.2 8.9%

Last update: 2025-09-04 10:00

IRTC Fundamental Data Overview

Market Cap USD = 5.67b (5.67b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 545.5m USD (Cash And Short Term Investments, last quarter)
P/S = 8.6319
P/B = 54.7591
Beta = 1.407
Revenue TTM = 657.2m USD
EBIT TTM = -85.7m USD
EBITDA TTM = -65.4m USD
Long Term Debt = 648.0m USD (from longTermDebt, last quarter)
Short Term Debt = 16.4m USD (from shortTermDebt, last quarter)
Debt = 664.4m USD (Calculated: Short Term 16.4m + Long Term 648.0m)
Net Debt = 425.6m USD (from netDebt column, last quarter)
Enterprise Value = 5.79b USD (5.67b + Debt 664.4m - CCE 545.5m)
Interest Coverage Ratio = -6.90 (Ebit TTM -85.7m / Interest Expense TTM 12.4m)
FCF Yield = 0.48% (FCF TTM 27.9m / Enterprise Value 5.79b)
FCF Margin = 4.24% (FCF TTM 27.9m / Revenue TTM 657.2m)
Net Margin = -14.06% (Net Income TTM -92.4m / Revenue TTM 657.2m)
Gross Margin = 69.78% ((Revenue TTM 657.2m - Cost of Revenue TTM 198.6m) / Revenue TTM)
Tobins Q-Ratio = -7.21 (set to none) (Enterprise Value 5.79b / Book Value Of Equity -803.8m)
Interest Expense / Debt = 0.38% (Interest Expense 2.51m / Debt 664.4m)
Taxrate = 21.0% (US default)
NOPAT = -85.7m (EBIT -85.7m, no tax applied on loss)
Current Ratio = 5.02 (Total Current Assets 663.9m / Total Current Liabilities 132.2m)
Debt / Equity = 6.41 (Debt 664.4m / last Quarter total Stockholder Equity 103.7m)
Debt / EBITDA = -10.15 (Net Debt 425.6m / EBITDA -65.4m)
Debt / FCF = 23.83 (Debt 664.4m / FCF TTM 27.9m)
Total Stockholder Equity = 88.2m (last 4 quarters mean)
RoA = -9.59% (Net Income -92.4m, Total Assets 964.0m )
RoE = -104.7% (Net Income TTM -92.4m / Total Stockholder Equity 88.2m)
RoCE = -11.64% (Ebit -85.7m / (Equity 88.2m + L.T.Debt 648.0m))
RoIC = -11.66% (NOPAT -85.7m / Invested Capital 735.1m)
WACC = 8.61% (E(5.67b)/V(6.34b) * Re(9.58%)) + (D(664.4m)/V(6.34b) * Rd(0.38%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 100.0 | Cagr: 1.78%
Discount Rate = 9.58% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 68.78% ; FCFE base≈27.9m ; Y1≈22.6m ; Y5≈15.7m
Fair Price DCF = 7.04 (DCF Value 226.2m / Shares Outstanding 32.1m; 5y FCF grow -22.83% → 3.0% )
Revenue Correlation: 97.90 | Revenue CAGR: 23.76%
Rev Growth-of-Growth: 2.79
EPS Correlation: 18.76 | EPS CAGR: 15.44%
EPS Growth-of-Growth: 69.88

Additional Sources for IRTC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle